Logo for Mind Medicine (MindMed) Inc

Mind Medicine (MindMed) Investor Relations Material

Latest events

Logo for Mind Medicine (MindMed) Inc

Q1 2024

Mind Medicine (MindMed)
Logo for Mind Medicine (MindMed)

Q1 2024

8 May, 2024
Logo for Mind Medicine (MindMed)

Study Update

7 Mar, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Mind Medicine (MindMed) Inc

Access all reports
Mind Medicine, Inc. operates as a psychedelic medicine biotech company. They focus on discovering, developing, and deploying psychedelic inspired medicines and therapies to address addiction and mental illness. Mind Medicine's research management team is led by Jim DeKorne in Oakland, CA. Jim has discovered uses for psychedelics in a diverse range of fields since the 1960s. These healthcare applications span illness management and palliative care to prevention strategies in psychiatry and drug abuse treatment. The Company is also exploring treatments for post-traumatic stress disorder (PTSD), as well as to optimize performance in individuals engaged in occupations requiring focus, problem solving, and creative abilities, such as medical workers, pilots, nuclear facility technicians, and first responders. Mind Medicine intends to conduct clinical trials leading to Federal Drug Administration approval of its lead candidate MindMed™—a combination of psychotherapy with the non-hallucinogenic fractionated doses of DMT.